Top 10 Eszopiclone (Lunesta) Generic Manufacturers in Israel
The pharmaceutical market in Israel has shown significant growth, driven by advancements in drug manufacturing and increasing demand for generic medications. As of 2023, Israel’s pharmaceutical industry is estimated to be valued at approximately $5 billion, with generics representing a substantial portion of this market. The demand for sleep aids, particularly the generic form of Eszopiclone, known for its efficacy in treating insomnia, has been rising. In recent years, production volumes for generics have surpassed 60% of the total drug production in Israel, reflecting a robust trend toward cost-effective therapies.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers in the world, holding a significant market share in Israel’s pharmaceutical sector. In 2022, Teva reported a production volume of approximately 600 million units, with generics accounting for over 60% of its total sales. Teva’s Eszopiclone is recognized for its quality and accessibility, making it a leading choice among healthcare providers.
2. Mylan N.V. (Viatris)
Mylan, now part of Viatris, has established a strong presence in the Israeli generic market. Their production facilities in Israel contribute to a remarkable output of over 200 million generic units annually. Mylan’s Eszopiclone is well-regarded for its efficacy and competitive pricing, helping the company capture a significant portion of the insomnia treatment market.
3. Neopharma
Neopharma is a prominent generic manufacturer in Israel, known for its high-quality pharmaceutical products. The company produces around 150 million units of various medications each year, with a growing footprint in the sleep aid segment. Neopharma’s Eszopiclone has gained popularity due to its affordability and effective formulation.
4. Amdipharm Mercury (AMCo)
Amdipharm Mercury operates in the Israeli market with a focus on generic medications. The company has reported production figures of around 100 million units annually. Their version of Eszopiclone is gaining traction, particularly among pharmacies looking to provide patients with cost-effective alternatives to branded medications.
5. Dexcel Pharma
Dexcel Pharma is a well-established player in the Israeli pharmaceutical landscape, producing an array of generic medications. The company’s annual production is approximately 80 million units, and its Eszopiclone formulation is a key component of its product lineup, favored for its reliability and effectiveness.
6. Amgen Israel
Though primarily known for its biologics, Amgen has ventured into the generic pharmaceutical market in Israel. The company produces over 70 million units of various medications, including Eszopiclone. Amgen’s commitment to quality has positioned its generic offerings favorably within the competitive landscape.
7. Taro Pharmaceutical Industries Ltd.
Taro is a major player in the Israeli pharmaceutical market, producing both branded and generic medications. With an annual output of around 60 million units, Taro’s Eszopiclone has been well-received, leveraging the company’s reputation for high-quality production standards.
8. Clalit Health Services
Clalit, primarily a health services provider, has made strides in the pharmaceutical industry by manufacturing generic medications. They produce around 50 million units annually, and their Eszopiclone product is aimed at improving patient adherence to insomnia treatment protocols.
9. Plantex
Plantex focuses on generic pharmaceuticals and natural products, contributing to the Israeli market with an annual production of approximately 45 million units. Their Eszopiclone formulation is positioned as a natural alternative, appealing to a niche market segment seeking holistic treatment options.
10. GSK Israel (GlaxoSmithKline)
While GSK is more recognized for its branded pharmaceuticals, its involvement in the generic sector in Israel includes the production of Eszopiclone. The company has reported production of around 30 million units, leveraging its established distribution network to reach a broad audience in need of sleep aids.
Insights
The generic pharmaceutical market in Israel, particularly for Eszopiclone, continues to expand, driven by a growing demand for cost-effective sleep aids amid rising insomnia rates. As of 2023, the generic market is projected to grow at a CAGR of 6.5%, reflecting increased awareness and acceptance of generic medications among healthcare providers and patients. The competitive landscape is expected to intensify, with key players focusing on quality and pricing to capture market share. Innovations in manufacturing and regulatory support will also play critical roles in shaping the future of the generic Eszopiclone market in Israel.
Related Analysis: View Previous Industry Report
